These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3470166)

  • 1. Elimination of enoxacin in renal disease.
    Bury RW; Becker GJ; Kincaid-Smith PS; Moulds RF; Whitworth JA
    Clin Pharmacol Ther; 1987 Apr; 41(4):434-8. PubMed ID: 3470166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin.
    Nix DE; Schultz RW; Frost RW; Sedman AJ; Thomas DJ; Kinkel AW; Schentag JJ
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():87-95. PubMed ID: 3162906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.
    Wolf R; Eberl R; Dunky A; Mertz N; Chang T; Goulet JR; Latts J
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():63-9. PubMed ID: 6389476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of enoxacin in elderly patients.
    Wise R; Baker SL; Misra M; Griggs D
    J Antimicrob Chemother; 1987 Mar; 19(3):343-50. PubMed ID: 3471751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue penetration of enoxacin.
    Wise R; Lockley R; Dent J; Webberly M
    Antimicrob Agents Chemother; 1984 Jul; 26(1):17-9. PubMed ID: 6591851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.
    Van der Auwera P; Stolear JC; George B; Dudley MN
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1491-7. PubMed ID: 2221856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of age on the pharmacokinetics of enoxacin.
    Dobbs BR; Gazeley LR; Campbell AJ; Edwards IR
    Eur J Clin Pharmacol; 1987; 33(1):101-4. PubMed ID: 3480221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance liquid chromatography and preliminary pharmacokinetics of enoxacin and its 4-oxo metabolite in human plasma, urine and saliva.
    Vree TB; Baars AM; Wijnands WJ
    J Chromatogr; 1985 Oct; 343(2):449-54. PubMed ID: 3864785
    [No Abstract]   [Full Text] [Related]  

  • 10. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.
    Toon S; Hopkins KJ; Garstang FM; Aarons L; Sedman A; Rowland M
    Clin Pharmacol Ther; 1987 Jul; 42(1):33-41. PubMed ID: 3474093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The absorption and disposition of enoxacin in healthy subjects.
    Somogyi AA; Bochner F
    J Clin Pharmacol; 1988 Aug; 28(8):707-13. PubMed ID: 3216037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of enoxacin in subjects with renal or hepatic impairment.
    Novelli A; Reali EF; Amato M; Dami A; Fallani S; Periti P
    J Chemother; 1989 Jul; 1(4 Suppl):546-8. PubMed ID: 16312526
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function.
    Pearson JG; Antal EJ; Raehl CL; Gorsch HK; Craig WA; Albert KS; Welling PG
    Clin Pharmacol Ther; 1986 Mar; 39(3):318-24. PubMed ID: 3081293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
    Wise R; Lockley R; Webberly M; Adhami ZN
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():75-81. PubMed ID: 6238932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxacin distribution in human tissues after multiple oral administration.
    Malmborg AS; Rannikko S
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():57-60. PubMed ID: 3162902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on enoxacin absorption.
    Somogyi AA; Bochner F; Keal JA; Rolan PE; Smith M
    Antimicrob Agents Chemother; 1987 Apr; 31(4):638-9. PubMed ID: 3475034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():67-77. PubMed ID: 3162904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxacin--a potent inhibitor of theophylline metabolism.
    Beckmann J; Elsässer W; Gundert-Remy U; Hertrampf R
    Eur J Clin Pharmacol; 1987; 33(3):227-30. PubMed ID: 3480222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.